98.78 0.00 (0.00%)
After hours: 5:16PM EST
|Bid||80.06 x 1100|
|Ask||132.00 x 900|
|Day's Range||96.60 - 99.14|
|52 Week Range||79.96 - 131.54|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||127.43|
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease. “With national reimbursement for Perceval, an innovative and trusted valve platform, we can provide patients and clinicians in Japan with an innovative and effective option for aortic heart valve replacement,” said Noriaki Kawana, President of LivaNova Japan. As the only 100-percent sutureless valve for aortic valve replacement, Perceval is designed to be highly versatile and suitable for a wide range of surgical approaches, including traditional and minimally invasive.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova PLC (LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for Treatment-Resistant Depression (TRD). Per its final decision, CMS has modified the NCD for VNS Therapy for TRD to include feedback received during the comment period in a manner that aligns the Coverage with Evidence Development (CED) framework with current indications and standard of practice for clinical study design in this disease state.
LivaNova PLC NASDAQ/NGS:LIVNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for LIVN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LIVN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LIVN totaled $1.95 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LivaNova PLC (LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on Wednesday, Feb. 27, 2019 at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth quarter and full-year 2018 results prior to the call.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval®. The results from the Perceval Aortic Heart Valve Study in North America, performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), were published in the Journal of Thoracic and Cardiovascular Surgery1.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it has joined forces with actor and epilepsy advocate Greg Grunberg. The partnership kicked off at the Epilepsy Awareness Day at Disneyland Education Expo, where Grunberg joined LivaNova to raise awareness of seizures, drug-resistant epilepsy (DRE) and the available treatment options.
LivaNova PLC (LIVN), a market-leading medical technology company, today commented on the U.S. Centers for Medicare & Medicaid Services (CMS) Proposed Decision Memo regarding its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for Treatment-Resistant Depression (TRD). Within the Proposed Decision Memo, CMS proposes to change the NCD for VNS Therapy for TRD to expand Medicare coverage.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions during the Piper Jaffray 30th Annual Healthcare Conference in New York and at the Berenberg European Conference 2018 in London. The discussion at the Piper Jaffray conference is scheduled to begin at 11 a.m. Eastern Time on Wednesday, Nov. 28, and the discussion at the Berenberg conference is scheduled to begin at 4 p.m. Greenwich Mean Time on Wednesday, Dec. 5. The Piper Jaffray discussion will be available to all interested parties through a live audiocast accessible via the Investor Relations section of LivaNova's website at www.livanova.com.
LivaNova (LIVN) delivered earnings and revenue surprises of -10.34% and -0.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018.
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that Damien McDonald, Chief Executive Officer, will present at the Stifel 2018 Healthcare Conference on Tuesday, Nov. 13 in New York at 9:30 a.m. Eastern Standard Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.